These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2023 related items for PubMed ID: 27101131

  • 1. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K.
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [Abstract] [Full Text] [Related]

  • 2. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS.
    Curr Vasc Pharmacol; 2020 Jun; 18(2):172-181. PubMed ID: 30961499
    [Abstract] [Full Text] [Related]

  • 3. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C.
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [Abstract] [Full Text] [Related]

  • 4. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
    Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, Tio F, Hardies J, Darland C, Musi N, Webb A, Portillo-Sanchez P.
    Ann Intern Med; 2016 Sep 06; 165(5):305-15. PubMed ID: 27322798
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological management of nonalcoholic fatty liver disease.
    Barb D, Portillo-Sanchez P, Cusi K.
    Metabolism; 2016 Aug 06; 65(8):1183-95. PubMed ID: 27301803
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G.
    Diabetes Metab; 2020 Nov 06; 46(6):427-441. PubMed ID: 31923578
    [Abstract] [Full Text] [Related]

  • 7. Diagnosis of non-alcoholic fatty liver disease (NAFLD).
    Yki-Järvinen H.
    Diabetologia; 2016 Jun 06; 59(6):1104-11. PubMed ID: 27091184
    [Abstract] [Full Text] [Related]

  • 8. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J, Cusi K.
    Curr Diab Rep; 2020 Oct 05; 20(11):59. PubMed ID: 33015726
    [Abstract] [Full Text] [Related]

  • 9. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
    Bril F, Kalavalapalli S, Clark VC, Lomonaco R, Soldevila-Pico C, Liu IC, Orsak B, Tio F, Cusi K.
    Clin Gastroenterol Hepatol; 2018 Apr 05; 16(4):558-566.e2. PubMed ID: 29223443
    [Abstract] [Full Text] [Related]

  • 10. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G, Mikhailidis DP, Sahebkar A.
    Metabolism; 2019 Dec 05; 101():154001. PubMed ID: 31672448
    [Abstract] [Full Text] [Related]

  • 11. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
    Patel Chavez C, Cusi K, Kadiyala S.
    J Clin Endocrinol Metab; 2022 Jan 01; 107(1):29-38. PubMed ID: 34406410
    [Abstract] [Full Text] [Related]

  • 12. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Doumas M, Imprialos K, Stavropoulos K, Athyros VG.
    Curr Vasc Pharmacol; 2019 Jan 01; 17(5):425-428. PubMed ID: 31418344
    [Abstract] [Full Text] [Related]

  • 13. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.
    Zachou M, Flevari P, Nasiri-Ansari N, Varytimiadis C, Kalaitzakis E, Kassi E, Androutsakos T.
    Eur J Clin Pharmacol; 2024 Jan 01; 80(1):127-150. PubMed ID: 37938366
    [Abstract] [Full Text] [Related]

  • 14. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
    Shyangdan D, Clar C, Ghouri N, Henderson R, Gurung T, Preiss D, Sattar N, Fraser A, Waugh N.
    Health Technol Assess; 2011 Nov 01; 15(38):1-110. PubMed ID: 22059955
    [Abstract] [Full Text] [Related]

  • 15. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
    Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Hecht J, Tio F, Cusi K.
    J Clin Endocrinol Metab; 2017 Aug 01; 102(8):2950-2961. PubMed ID: 28575232
    [Abstract] [Full Text] [Related]

  • 16. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM, Sanyal AJ.
    Liver Int; 2017 Jan 01; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [Abstract] [Full Text] [Related]

  • 17. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
    Stein LL, Dong MH, Loomba R.
    Adv Ther; 2009 Oct 01; 26(10):893-907. PubMed ID: 19921118
    [Abstract] [Full Text] [Related]

  • 18. [Non-alcoholic fatty liver disease and type 2 diabetes mellitus. II. Treatment].
    Pár A, Wittmann I, Pár G.
    Orv Hetil; 2022 May 29; 163(22):855-862. PubMed ID: 35895614
    [Abstract] [Full Text] [Related]

  • 19. Pioglitazone for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes.
    Ann Intern Med; 2016 Sep 06; 165(5):. PubMed ID: 27322943
    [No Abstract] [Full Text] [Related]

  • 20. Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
    Lomonaco R, Sunny NE, Bril F, Cusi K.
    Drugs; 2013 Jan 06; 73(1):1-14. PubMed ID: 23329465
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 102.